Key Financial Performance (Q1 FY27 vs Q1 FY26)

  • Total Income: ₹887.33 million (up 20.7% from ₹734.92 million)
  • EBITDA: ₹315.30 million (up 27.9% from ₹246.56 million)
  • EBITDA Margin: 36.0% (vs 34.0%)
  • PAT: ₹128.45 million (up 40.0% from ₹91.75 million)
  • PAT Margin: 14.7% (vs 12.6%)

Full Year Comparison (FY26 vs FY25)

  • Total Income: ₹3,135.78 million (up 22.5% from ₹2,559.39 million)
  • EBITDA: ₹985.58 million (up 15.8% from ₹850.88 million)
  • EBITDA Margin: 31.8% (vs 33.8%)
  • PAT: ₹314.04 million (up 1.4% from ₹309.78 million)
  • PAT Margin: 10.1% (vs 12.3%)

Operational Highlights (Q1 FY27 vs Q1 FY26)

  • Total Patients: 0.38 million (up 12.1% from 0.33 million)
  • Total Tests: 2.10 million (up 8.9% from 1.92 million)
  • Tests per Patient: 5.56 (down 2.8% from 5.72)
  • Average Revenue per Test: ₹418 (up 10.6% from ₹377)
  • Average Revenue per Patient: ₹2,321 (up 10.5% from ₹2,101)

Full Year Operational Metrics

  • Total Patients (FY26): 1.37 million
  • Total Tests (FY26): 8.16 million
  • Tests per Patient (FY26): 5.95
  • Average Revenue per Test (FY26): ₹381
  • Average Revenue per Patient (FY26): ₹2,264

Management Commentary

Mrs. Ritu Mittal, Joint Managing Director & CEO, stated that the company started FY27 with strong growth across volumes and realizations. The quarter witnessed healthy growth in both patient and test volumes, reflecting continued strength in underlying consumer demand.

The company expanded its network during the quarter by commissioning one hub and three spoke centers, in line with its strategy of building clusters and increasing density around them.

Suraksha Genomics delivered revenue growth of 136% YoY in Q1 FY27, marking the fifth consecutive quarter of sequential growth. The company believes genomics has the potential to emerge as an increasingly meaningful contributor to the business over the coming years.

Company Background

Suraksha Diagnostic Limited is the largest integrated diagnostic chain in East India with presence in West Bengal, Bihar, and Assam. The company provides integrated solutions in pathology and radiology testing, as well as medical consultation services.

The central reference laboratory is accredited by the College of American Pathologists, while 4 laboratories hold NABL accreditation, and 3 advanced diagnostic centres are accredited by NABH.

Event Timing

  • Date of occurrence: 12 August 2026
  • Time of occurrence: 04:30 P.M. (IST)

Corporate Identification